[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.

Austin Ryan Pantel Sarah B Gitto Mehran Makvandi Hyoung Kim Sergey Medvedv Joanna K Weeks Drew A Torigian Chia-Ju Hsieh Benjamin Ferman Nawar A Latif Janos L Tanyi Lainie P Martin Shannon M Lanzo Fang Liu Quy Cao Gordon B Mills Robert K Doot David A Mankoff Robert H Mach Lilie L Lin Fiona Simpkins

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The decline in [18F]FTT uptake shortly after PARPi initiation provides a measure of drug-target engagement and shows promise as a biomarker to guide PARPi therapies in this pilot study. These results support additional pre-clinical mechanistic and clinical studies in subjects receiving PARPi +/- combination therapy.

Keyphrases

combination therapy
pet imaging
social media
dna damage
positron emission tomography
drug induced
big data
computed tomography
oxidative stress
machine learning
artificial intelligence